
|Videos|April 15, 2022
Efficacy Data from the VISION Trial of Lu 177 Vipivotide Tetraxetan
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































